We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Celadon Pharmaceuticals Plc | LSE:SWC | London | Ordinary Share | Ordinary Shares |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 147.50 | 140.00 | 155.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2021 to Apr 2024
TIDMSWC
RNS Number : 7130P
Summerway Capital PLC
20 October 2021
20 October 2021
Summerway Capital Plc
("Summerway" or the "Company")
Result of General Meeting
Following the General Meeting of the Company, which was held earlier today, the Board is pleased to announce that the ordinary resolution set out in the Notice of General Meeting was duly passed. Details of the number of proxy votes cast for, against and withheld on the resolution will be published on the Company's website at https://www.summerwaycapital.co.uk/.
The Company's investing policy has now been amended and the Company looks forward to pursuing its revised strategic focus and advancing current discussions with an immediate opportunity within the healthcare and pharmaceutical sector.
This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.
Enquiries:
Summerway Capital Plc
Tony Morris 020 7440 7520 Canaccord Genuity Limited (Nominated Adviser and Broker) Andrew Potts 020 7523 8000
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ROMDKKBNQBDDDKB
(END) Dow Jones Newswires
October 20, 2021 10:35 ET (14:35 GMT)
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
